171 related articles for article (PubMed ID: 36485164)
21. Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens.
Jain P; Gu J; Kanagal-Shamanna R; Tang Z; Patel KP; Yao H; Fang L; Bao HY; Liu CH; Lin P; Medeiros LJ; Lu X
Leuk Res; 2019 Sep; 84():106176. PubMed ID: 31279181
[TBL] [Abstract][Full Text] [Related]
22. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
23. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
24. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
25. SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Short NJ; Kantarjian H; Jabbour E
Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):61-66. PubMed ID: 34561201
[TBL] [Abstract][Full Text] [Related]
26. High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.
Roberts KG; Gu Z; Payne-Turner D; McCastlain K; Harvey RC; Chen IM; Pei D; Iacobucci I; Valentine M; Pounds SB; Shi L; Li Y; Zhang J; Cheng C; Rambaldi A; Tosi M; Spinelli O; Radich JP; Minden MD; Rowe JM; Luger S; Litzow MR; Tallman MS; Wiernik PH; Bhatia R; Aldoss I; Kohlschmidt J; Mrózek K; Marcucci G; Bloomfield CD; Stock W; Kornblau S; Kantarjian HM; Konopleva M; Paietta E; Willman CL; Mullighan CG
J Clin Oncol; 2017 Feb; 35(4):394-401. PubMed ID: 27870571
[TBL] [Abstract][Full Text] [Related]
27. The role of E255K/V-inclusive mutations in a Philadelphia-positive acute lymphoblastic leukemia with mutation evolution during sequential TKIs therapies: A case report.
Zhao M; Gui X; Wu Q; Xia L; Wang Y
Medicine (Baltimore); 2021 May; 100(18):e25579. PubMed ID: 33950935
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Piccaluga PP; Paolini S; Martinelli G
Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
[TBL] [Abstract][Full Text] [Related]
29. Diagnostics and treatment challenges of Ph-like acute lymphoblastic leukemia: a description of 3 clinical cases.
Zarubina KI; Parovichnikova EN; Baskhaeva GA; Krasilnikova AE; Gavrilina OA; Biderman BV; Sudarikov AB; Bondarenko SN; Davydova YO; Galtseva IV; Sokolov AN; Troitskaya VV; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):110-117. PubMed ID: 30701932
[TBL] [Abstract][Full Text] [Related]
30. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL.
Hurtz C; Wertheim GB; Loftus JP; Blumenthal D; Lehman A; Li Y; Bagashev A; Manning B; Cummins KD; Burkhardt JK; Perl AE; Carroll M; Tasian SK
J Clin Invest; 2020 Jul; 130(7):3637-3653. PubMed ID: 32191635
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study.
Aubert L; Petit A; Bertrand Y; Ray-Lunven AF; Angoso M; Pluchart C; Millot F; Saultier P; Cheikh N; Pellier I; Plantaz D; Sirvent A; Thouvenin-Doublet S; Valduga J; Plat G; Rialland F; Henry C; Esvan M; Gandemer V
Pediatr Blood Cancer; 2022 Feb; 69(2):e29441. PubMed ID: 34854546
[TBL] [Abstract][Full Text] [Related]
32. Curing Ph+ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant.
Fielding AK
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):24-29. PubMed ID: 31808885
[TBL] [Abstract][Full Text] [Related]
33. The presence of Philadelphia chromosome does not confer poor prognosis in adult pre-B acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era - a surveillance, epidemiology, and end results database analysis.
Igwe IJ; Yang D; Merchant A; Merin N; Yaghmour G; Kelly K; Ramsingh G
Br J Haematol; 2017 Nov; 179(4):618-626. PubMed ID: 29047122
[TBL] [Abstract][Full Text] [Related]
34. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
35. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.
Jain N; Roberts KG; Jabbour E; Patel K; Eterovic AK; Chen K; Zweidler-McKay P; Lu X; Fawcett G; Wang SA; Konoplev S; Harvey RC; Chen IM; Payne-Turner D; Valentine M; Thomas D; Garcia-Manero G; Ravandi F; Cortes J; Kornblau S; O'Brien S; Pierce S; Jorgensen J; Shaw KR; Willman CL; Mullighan CG; Kantarjian H; Konopleva M
Blood; 2017 Feb; 129(5):572-581. PubMed ID: 27919910
[TBL] [Abstract][Full Text] [Related]
36. Beyond Philadelphia: 'Ph-like' B cell precursor acute lymphoblastic leukemias - diagnostic challenges and therapeutic promises.
Izraeli S
Curr Opin Hematol; 2014 Jul; 21(4):289-96. PubMed ID: 24848770
[TBL] [Abstract][Full Text] [Related]
37. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
Reshmi SC; Harvey RC; Roberts KG; Stonerock E; Smith A; Jenkins H; Chen IM; Valentine M; Liu Y; Li Y; Shao Y; Easton J; Payne-Turner D; Gu Z; Tran TH; Nguyen JV; Devidas M; Dai Y; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Angiolillo AL; Burke MJ; Salzer WL; Zweidler-McKay PA; Rabin KR; Carroll WL; Zhang J; Loh ML; Mullighan CG; Willman CL; Gastier-Foster JM; Hunger SP
Blood; 2017 Jun; 129(25):3352-3361. PubMed ID: 28408464
[TBL] [Abstract][Full Text] [Related]
38. Emerging tyrosine kinase inhibitors for the treatment of adult acute lymphoblastic leukemia.
Ansuinelli M; Cesini L; Chiaretti S; Foà R
Expert Opin Emerg Drugs; 2021 Sep; 26(3):281-294. PubMed ID: 34259120
[No Abstract] [Full Text] [Related]
39. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
[TBL] [Abstract][Full Text] [Related]
40. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.
Mullighan CG
Clin Cancer Res; 2011 Feb; 17(3):396-400. PubMed ID: 21149616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
